Author/Authors :
Babaie, Delara Department of Immunology and Allergy - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Shamsian, Bibi Shahin Pediatric Congenital Hematologic Disorders Research Center - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Momtazmanesh, Nader Department of Pediatric Hematology and Oncology - Loghman-e- Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Godarzipour, Hamidreza Pediatric Congenital Hematologic Disorders Research Center - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Amirmoini, Mehrdad Department of Immunology and Allergy - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Bashardoust, Bahram Department of Immunology and Allergy - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ebrahimi, Masoomeh Department of Pediatrics - Loghman-e- Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Vahedi, Mahdieh Department of Immunology and Allergy - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ghaemi, Reza Department of Pediatrics - Urmia University of Medical Sciences, Urmia, Iran , Mesdaghi, Mehrnaz Department of Immunology and Allergy - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Usage of cancer chemotherapeutics drugs can be associated with adverse drug reactions.
When IgE-mediated drug reactions are formed following administration of a chemotherapeutics
drug that is a drug of choice, drug desensitization protocols can be helpful. HSR can be
allergic or nonallergic, but the clinical manifestations are similar. RDD is effective when
used appropriately, however it is often over utilized instead of performing a drug challenge.
RDD is both an acceptable approach and a high-risk treatment modality in patients, in whom
the offending agent is the first choice in chemotherapy. The safety of this modality has been
acceptable in large studies. The side effects are often less frequent and less severe by repeating
the protocol. We present 4 cases of successful desensitization in cancer patients, who have
developed IgE- mediated reactions to their major chemotherapy drug.
Keywords :
Drug desensitization , Drug hypersensitivity syndromes , Cancer chemotherapy drugs , Adverse drug reaction
